CVS Health (CVS) unit Aetna on Friday revised its policy to state that colorectal cancer screening is considered medically necessary for average-risk persons aged 45 years and older when recommended by their physician, Baird analyst Catherine Ramsey Schulte tells investors in a research note. Aetna's previous version covered for average-risk persons beginning at age 50 years, the analyst points out. While admitting further uptake in ages 45-49 will require medical education among doctors, Ramsey Schulte views Aetne'a update as "incrementally positive" for Exact Sciences. She keeps an Outperform rating on the shares with a $102 price target. The stock in early trading is up 1% to $93.57.